In the wake of disappointing clinical results for an experimental breast cancer drug,...

In the wake of disappointing clinical results for an experimental breast cancer drug, Sanofi-Aventis (SNY) gets more bad news. An Australian court ruled that SNY waited too long to object to the introduction of generic forms of Taxotere, and that Hospira (HSP) and Interpharma may proceed with the introduction of their generic rivals. Taxotere makes up about 95% of Sanofi's Australian oncology business.